Saxagliptin and Atherosclerosis (SAXATH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01552018|
Recruitment Status : Completed
First Posted : March 13, 2012
Last Update Posted : June 18, 2014
Dipeptidyl peptidase 4 (DPP-4) inhibitors are approved as add on therapy to improve glycaemic control in Type 2 Diabetes Mellitus (T2DM). DPP-4 inactivates the incretin hormone glucagon-like peptide 1 (GLP-1). Inhibiting the inactivation of GLP-1 leads to increased insulin- and reduced glucagon secretion after meals. DPP-4 has been shown to be present in atherosclerotic plaques. DPP-4 is a protease with substrates including cytokines and chemokines associated with atherosclerosis/inflammation.
The purpose of this study is to explore the effects of 3 months intervention with DPP-4 inhibitor saxagliptin on biomarkers related to atherosclerosis in patients with stable coronary artery disease (CAD) and T2DM, on circulating levels and on expression levels in circulating monocytes and adipose tissue.
A reduction in markers associated with atherosclerosis could indicate an antiatherosclerotic effect of DPP-4 inhibitors beyond glycaemic control alone.
Due to reduced sample size (recruitment problems) the main focus has changed and will now be on cellular aspects and gene regulation (initially secondary outcome measure).
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Diabetes Mellitus Type 2||Drug: Saxagliptin Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
Active Comparator: Saxagliptin
Saxagliptin 5 mg/day
Saxagliptin 5 mg, 1 tablet per day for 3 months
Other Name: Onglyza
Placebo Comparator: Placebo
Placebo, 1 tablet per day for 3 months.
- Inflammatory biomarkers [ Time Frame: Changes in biomarkers from baseline to 3 months ]A selection of biomarkers associated with atherosclerosis, circulating levels and gene expression levels in adipose tissue and leukocytes.
- Gene expression of DPP-4 in adipose tissue and leukocytes [ Time Frame: Change in expression level of DPP-4 from baseline to 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01552018
|Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal|
|Oslo, Norway, N-0424|
|Principal Investigator:||Ida U Njerve, MD||Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Norway|